Treatment of Non-Hodgkin's Lymphoma (NHL) with radiolabeled antibodies (mAbs)

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Most patients with non-Hodgkin's lymphoma (NHL) achieve remission but, despite newer drugs, the natural history of this disease has not improved during the last 20 years. Less than one half of patients with aggressive NHL are cured, and few of those with low-grade NHL are curable. Furthermore, NHL becomes progressively more chemoresistant while remaining responsive to external beam radiation therapy. Radioimmunotherapy (RIT) is a logical strategy for the treatment of NHL because this disease is multifocal and radiosensitive. Because of their remarkable effectiveness for RIT, 2 anti-CD20 monoclonal antibodies (mAbs), one labeled with 111In for imaging or 90Y for therapy and a second labeled with 131I for imaging and therapy, have been approved for use in patients with NHL. These drugs have proven remarkably effective and safe. Evidence for the importance of the radionuclide is manifested by the data in the randomized pivotal phase III trial of 90Y-ibritumomab that revealed response rates were several times greater in the 90Y-ibritumomab arm than in the rituximab arm. A second drug for RIT, 131I-tositumomab, was compared in a pivotal trial with the efficacy of the last chemotherapy received by each patient. Once again, response rates were much higher for RIT. Both 90Y-ibritumomab and 131I-tositumomab require preinfusion of several hundred milligrams of unlabeled anti-CD20 mAb to obtain "favorable" biodistribution, that is, targeting of NHL. Response rates for other mAbs and radionuclides in NHL also have been high but these drugs have not reached the approval stage. These drugs can be used safely by physicians who have suitable training and judgment. Unlike chemotherapy, RIT is not associated with mucositis, hair loss, or persistent nausea or vomiting. Although hematologic toxicity is dose limiting, hospitalization for febrile neutropenia is uncommon. Randomized trials of RIT in different formulations have not been conducted, but there is evidence to suggest that the mAb, antigen, radionuclide, chelator, linker, and dosing strategy may make a difference in the outcome.

Original languageEnglish (US)
Pages (from-to)202-211
Number of pages10
JournalSeminars in Nuclear Medicine
Volume35
Issue number3 SPEC. ISS.
DOIs
StatePublished - Jul 2005

Fingerprint

Non-Hodgkin's Lymphoma
Radioimmunotherapy
Monoclonal Antibodies
Antibodies
Radioisotopes
Pharmaceutical Preparations
Therapeutics
Drug Therapy
Febrile Neutropenia
Mucositis
Alopecia
Chelating Agents
Nausea
Vomiting
Hospitalization
Radiotherapy
Physicians
Antigens

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Treatment of Non-Hodgkin's Lymphoma (NHL) with radiolabeled antibodies (mAbs). / Denardo, Gerald L.

In: Seminars in Nuclear Medicine, Vol. 35, No. 3 SPEC. ISS., 07.2005, p. 202-211.

Research output: Contribution to journalArticle

@article{25c40424fe7845bd875bf1e5447b3a67,
title = "Treatment of Non-Hodgkin's Lymphoma (NHL) with radiolabeled antibodies (mAbs)",
abstract = "Most patients with non-Hodgkin's lymphoma (NHL) achieve remission but, despite newer drugs, the natural history of this disease has not improved during the last 20 years. Less than one half of patients with aggressive NHL are cured, and few of those with low-grade NHL are curable. Furthermore, NHL becomes progressively more chemoresistant while remaining responsive to external beam radiation therapy. Radioimmunotherapy (RIT) is a logical strategy for the treatment of NHL because this disease is multifocal and radiosensitive. Because of their remarkable effectiveness for RIT, 2 anti-CD20 monoclonal antibodies (mAbs), one labeled with 111In for imaging or 90Y for therapy and a second labeled with 131I for imaging and therapy, have been approved for use in patients with NHL. These drugs have proven remarkably effective and safe. Evidence for the importance of the radionuclide is manifested by the data in the randomized pivotal phase III trial of 90Y-ibritumomab that revealed response rates were several times greater in the 90Y-ibritumomab arm than in the rituximab arm. A second drug for RIT, 131I-tositumomab, was compared in a pivotal trial with the efficacy of the last chemotherapy received by each patient. Once again, response rates were much higher for RIT. Both 90Y-ibritumomab and 131I-tositumomab require preinfusion of several hundred milligrams of unlabeled anti-CD20 mAb to obtain {"}favorable{"} biodistribution, that is, targeting of NHL. Response rates for other mAbs and radionuclides in NHL also have been high but these drugs have not reached the approval stage. These drugs can be used safely by physicians who have suitable training and judgment. Unlike chemotherapy, RIT is not associated with mucositis, hair loss, or persistent nausea or vomiting. Although hematologic toxicity is dose limiting, hospitalization for febrile neutropenia is uncommon. Randomized trials of RIT in different formulations have not been conducted, but there is evidence to suggest that the mAb, antigen, radionuclide, chelator, linker, and dosing strategy may make a difference in the outcome.",
author = "Denardo, {Gerald L}",
year = "2005",
month = "7",
doi = "10.1053/j.semnuclmed.2005.02.006",
language = "English (US)",
volume = "35",
pages = "202--211",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3 SPEC. ISS.",

}

TY - JOUR

T1 - Treatment of Non-Hodgkin's Lymphoma (NHL) with radiolabeled antibodies (mAbs)

AU - Denardo, Gerald L

PY - 2005/7

Y1 - 2005/7

N2 - Most patients with non-Hodgkin's lymphoma (NHL) achieve remission but, despite newer drugs, the natural history of this disease has not improved during the last 20 years. Less than one half of patients with aggressive NHL are cured, and few of those with low-grade NHL are curable. Furthermore, NHL becomes progressively more chemoresistant while remaining responsive to external beam radiation therapy. Radioimmunotherapy (RIT) is a logical strategy for the treatment of NHL because this disease is multifocal and radiosensitive. Because of their remarkable effectiveness for RIT, 2 anti-CD20 monoclonal antibodies (mAbs), one labeled with 111In for imaging or 90Y for therapy and a second labeled with 131I for imaging and therapy, have been approved for use in patients with NHL. These drugs have proven remarkably effective and safe. Evidence for the importance of the radionuclide is manifested by the data in the randomized pivotal phase III trial of 90Y-ibritumomab that revealed response rates were several times greater in the 90Y-ibritumomab arm than in the rituximab arm. A second drug for RIT, 131I-tositumomab, was compared in a pivotal trial with the efficacy of the last chemotherapy received by each patient. Once again, response rates were much higher for RIT. Both 90Y-ibritumomab and 131I-tositumomab require preinfusion of several hundred milligrams of unlabeled anti-CD20 mAb to obtain "favorable" biodistribution, that is, targeting of NHL. Response rates for other mAbs and radionuclides in NHL also have been high but these drugs have not reached the approval stage. These drugs can be used safely by physicians who have suitable training and judgment. Unlike chemotherapy, RIT is not associated with mucositis, hair loss, or persistent nausea or vomiting. Although hematologic toxicity is dose limiting, hospitalization for febrile neutropenia is uncommon. Randomized trials of RIT in different formulations have not been conducted, but there is evidence to suggest that the mAb, antigen, radionuclide, chelator, linker, and dosing strategy may make a difference in the outcome.

AB - Most patients with non-Hodgkin's lymphoma (NHL) achieve remission but, despite newer drugs, the natural history of this disease has not improved during the last 20 years. Less than one half of patients with aggressive NHL are cured, and few of those with low-grade NHL are curable. Furthermore, NHL becomes progressively more chemoresistant while remaining responsive to external beam radiation therapy. Radioimmunotherapy (RIT) is a logical strategy for the treatment of NHL because this disease is multifocal and radiosensitive. Because of their remarkable effectiveness for RIT, 2 anti-CD20 monoclonal antibodies (mAbs), one labeled with 111In for imaging or 90Y for therapy and a second labeled with 131I for imaging and therapy, have been approved for use in patients with NHL. These drugs have proven remarkably effective and safe. Evidence for the importance of the radionuclide is manifested by the data in the randomized pivotal phase III trial of 90Y-ibritumomab that revealed response rates were several times greater in the 90Y-ibritumomab arm than in the rituximab arm. A second drug for RIT, 131I-tositumomab, was compared in a pivotal trial with the efficacy of the last chemotherapy received by each patient. Once again, response rates were much higher for RIT. Both 90Y-ibritumomab and 131I-tositumomab require preinfusion of several hundred milligrams of unlabeled anti-CD20 mAb to obtain "favorable" biodistribution, that is, targeting of NHL. Response rates for other mAbs and radionuclides in NHL also have been high but these drugs have not reached the approval stage. These drugs can be used safely by physicians who have suitable training and judgment. Unlike chemotherapy, RIT is not associated with mucositis, hair loss, or persistent nausea or vomiting. Although hematologic toxicity is dose limiting, hospitalization for febrile neutropenia is uncommon. Randomized trials of RIT in different formulations have not been conducted, but there is evidence to suggest that the mAb, antigen, radionuclide, chelator, linker, and dosing strategy may make a difference in the outcome.

UR - http://www.scopus.com/inward/record.url?scp=23744493939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744493939&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2005.02.006

DO - 10.1053/j.semnuclmed.2005.02.006

M3 - Article

C2 - 16098294

AN - SCOPUS:23744493939

VL - 35

SP - 202

EP - 211

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3 SPEC. ISS.

ER -